Apyx Medical Corporation (NASDAQ:APYX) watched its shares pretty much stand still Wednesday. The company, which manufactures a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration for the Renuvion Micro Handpiece, a new addition to the Renuvion product family. The Renuvion Micro Handpiece is cleared with an indication “for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.”
“The Renuvion Micro Handpiece represents a new addition to our Advanced Energy product portfolio, designed with the needs of our surgeon customers in the cosmetic surgery market in mind,” said CEO Charlie Goodwin.
“Most notably, our Renuvion Micro Handpiece features include a smaller instrument shaft, which is 10 cm long and 1.5mm wide, half the width of our Renuvion APR Handpiece. It complements our existing product portfolio, providing our customers with a new option to facilitate soft tissue contraction in those cases that may benefit from the use of a handpiece with a smaller profile. The Renuvion Micro Handpiece is designed for use with the Apyx One Console, our next-generation generator system which we launched at the beginning of 2023.”
APYX shares took on two cents to $6.94.
